Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.07 | 0.10 | -0.04 |
| FCF Yield | -20.42% | -42.28% | -29.42% | -17.53% |
| EV / EBITDA | -5.43 | -3.36 | -3.97 | -3.86 |
| Quality | ||||
| ROIC | -48.57% | -50.73% | -32.26% | -24.47% |
| Gross Margin | 91.64% | 89.14% | 88.45% | 85.92% |
| Cash Conversion Ratio | 0.80 | 0.86 | 0.97 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.63% | 3.11% | 0.67% | 26.40% |
| Free Cash Flow Growth | 33.39% | 17.57% | -38.61% | -7.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.66 | -1.00 | -0.24 | 0.27 |
| Interest Coverage | -5.49 | -6.98 | -8.24 | -8.24 |
| Efficiency | ||||
| Inventory Turnover | 0.11 | 0.18 | 0.15 | 0.42 |
| Cash Conversion Cycle | 419.88 | -101.92 | 6.47 | -93.85 |